Radiotherapy and Renal Cell Carcinoma: A Continuing Saga

Overview

Journal In Vivo

Specialty Oncology

Date 2021 Apr 29

PMID 33910814

Citations 3

Authors

Despoina Spyropoulou

Panagiotis Tsiganos

Foteinos-Ioannis Dimitrakopoulos

Maria Tolia

Angelos Koutras

Dimitris Velissaris

Maria Lagadinou

Nikolaos Papathanasiou

Areti Gkantaifi

Haralabos Kalofonos

Dimitrios Kardamakis

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma (RCC) is one of the most aggressive malignancies of the genito-urinary tract, having a poor prognosis especially in patients with metastasis. Surgical resection remains the gold standard for localized renal cancer disease, with radiotherapy (RT) receiving much skepticism during the last decades. However, many studies have evaluated the role of RT, and although renal cancer is traditionally considered radio-resistant, technological advances in the RT field with regards to modern linear accelerators, as well as advanced RT techniques have resulted in breakthrough therapeutic outcomes. Additionally, the combination of RT with immune checkpoint inhibitors and targeted agents may maximize the clinical benefit. This review article focuses on the role of RT in the therapeutic management of renal cell carcinoma.

Citing Articles

Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer.

He P, Ma L, Xu B, Wang Y, Li X, Chen H Ther Adv Med Oncol. 2024; 16:17588359241266156.

PMID: 39091604 PMC: 11292724. DOI: 10.1177/17588359241266156.

Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group.

Nguyen N, Chirila M, Page B, Vinh-Hung V, Gorobets O, Mohammadianpanah M Front Oncol. 2024; 14:1391464.

PMID: 38854736 PMC: 11162108. DOI: 10.3389/fonc.2024.1391464.

Altered NCR3 Splice Variants May Result in Deficient NK Cell Function in Renal Cell Carcinoma Patients.

Wang X, Huang L, Wen X, Li D, Yang G, Zheng J In Vivo. 2023; 38(1):174-183.

PMID: 38148073 PMC: 10756430. DOI: 10.21873/invivo.13423.

References

De Wolf K, Vermaelen K, De Meerleer G, Lambrecht B, Ost P . The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology. 2015; 4(10):e1042198. PMC: 4590014. DOI: 10.1080/2162402X.2015.1042198. View

Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R . Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol. 2010; 186(4):210-7. DOI: 10.1007/s00066-010-2055-z. View

Calvo F, Sole C, Martinez-Monge R, Azinovic I, Aristu J, Zudaire J . Intraoperative EBRT and resection for renal cell carcinoma : twenty-year outcomes. Strahlenther Onkol. 2012; 189(2):129-36. DOI: 10.1007/s00066-012-0272-3. View

Moraes F, Winter J, Atenafu E, Dasgupta A, Raziee H, Coolens C . Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose. Neuro Oncol. 2018; 21(2):242-251. PMC: 6374761. DOI: 10.1093/neuonc/noy159. View

Heinzer H, Huland E, Huland H . [Treatment of metastatic renal cell carcinoma. Value of immunotherapy compared with surgery of metastases]. Urologe A. 2000; 39(4):356-61. DOI: 10.1007/s001200050370. View

Correa R, Rodrigues G, Chen H, Warner A, Ahmad B, Louie A . Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations. Am J Clin Oncol. 2016; 41(6):568-575. DOI: 10.1097/COC.0000000000000329. View

Deschavanne P, Fertil B . A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys. 1996; 34(1):251-66. DOI: 10.1016/0360-3016(95)02029-2. View

Wardak Z, Bland R, Ahn C, Xie X, Chason D, Morrill K . A Phase 2 Clinical Trial of SABR Followed by Immediate Vertebroplasty for Spine Metastases. Int J Radiat Oncol Biol Phys. 2019; 104(1):83-89. DOI: 10.1016/j.ijrobp.2019.01.072. View

Flanigan R, Campbell S, Clark J, Picken M . Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003; 4(5):385-90. DOI: 10.1007/s11864-003-0039-2. View

10.

Meyer C, Sun M, Karam J, Leow J, de Velasco G, Pal S . Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. Eur Urol. 2017; 72(2):171-174. DOI: 10.1016/j.eururo.2017.03.005. View

11.

Buttigliero C, Allis S, Tucci M, Zichi C, Leone G, Di Stefano R . Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treat Rev. 2018; 69:215-223. DOI: 10.1016/j.ctrv.2018.07.010. View

12.

Stein M, Kuten A, Halpern J, Coachman N, Cohen Y, Robinson E . The value of postoperative irradiation in renal cell cancer. Radiother Oncol. 1992; 24(1):41-4. DOI: 10.1016/0167-8140(92)90352-u. View

13.

Habl G, Uhl M, Hensley F, Pahernik S, Debus J, Roder F . Intraoperative electron radiation therapy (IOERT) in patients with locally recurrent renal cell carcinoma. Radiat Oncol. 2013; 8:282. PMC: 3922867. DOI: 10.1186/1748-717X-8-282. View

14.

Hernandez L, Zamorano L, Sloan A, Fontanesi J, Lo S, Levin K . Gamma knife radiosurgery for renal cell carcinoma brain metastases. J Neurosurg. 2003; 97(5 Suppl):489-93. DOI: 10.3171/jns.2002.97.supplement. View

15.

Hartsell W, Scott C, Bruner D, Scarantino C, Ivker R, Roach 3rd M . Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005; 97(11):798-804. DOI: 10.1093/jnci/dji139. View

16.

Cannady S, Cavanaugh K, Lee S, Bukowski R, Olencki T, Stevens G . Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. Int J Radiat Oncol Biol Phys. 2003; 58(1):253-8. DOI: 10.1016/s0360-3016(03)00818-6. View

17.

Qayyum T, Oades G, Horgan P, Aitchison M, Edwards J . The epidemiology and risk factors for renal cancer. Curr Urol. 2014; 6(4):169-74. PMC: 3783274. DOI: 10.1159/000343534. View

18.

Paly J, Hallemeier C, Biggs P, Niemierko A, Roeder F, Martinez-Monge R . Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014; 88(3):618-23. DOI: 10.1016/j.ijrobp.2013.11.207. View

19.

Shibui S, Nishikawa R, Nomura K . [Treatment of metastatic brain tumor from renal cell carcinoma]. No Shinkei Geka. 1990; 18(10):935-8. View

20.

Dagan R, Lo S, Redmond K, Poon I, Foote M, Lohr F . A multi-national report on stereotactic body radiotherapy for oligometastases: Patient selection and follow-up. Acta Oncol. 2016; 55(5):633-7. DOI: 10.3109/0284186X.2015.1118659. View